No connection

Search Results

PIII

BEARISH
$2.5 Live
P3 Health Partners Inc. · NASDAQ
Target $3.5 (+40.0%)
$1.52 52W Range $11.3

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 17, 2026
Market cap
$507.93M
P/E
N/A
ROE
-6952.6%
Profit margin
-10.1%
Debt/Equity
N/A
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
95%
P3 Health Partners exhibits severe financial distress, characterized by a Piotroski F-Score of 4/9 which barely maintains a 'stable' rating despite catastrophic balance sheet metrics. The company is operating with negative equity (Price/Book: -0.05) and a critical liquidity crisis, evidenced by a Current Ratio of 0.24. Massive operating losses and a staggering ROE of -6952.57% indicate a failing business model. With a 5-year price decline of 99.5% and consistent earnings misses, the company faces significant insolvency risk.

Key Strengths

Low Price-to-Sales ratio (0.35) suggests low valuation relative to revenue
Marginal positive revenue growth (3.80% YoY)
Analyst target price ($3.50) sits above current market price
Piotroski F-Score of 4/9 prevents a 'weak' classification
Small market cap provides potential for high volatility spikes

Key Risks

Critical liquidity shortage with a Current Ratio of 0.24
Negative shareholder equity (Price/Book -0.05)
Extreme operational inefficiency with -39.98% operating margins
Consistent failure to meet earnings estimates (0/4 in last 4 quarters)
Severe long-term capital erosion (-99.5% 5-year return)

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
8
Weak
Value
10
Future
15
Past
5
Health
10
Dividend
0
AI Verdict
Distressed / High Bankruptcy Risk
Key drivers: Negative Equity, Liquidity Crisis, Catastrophic ROE, Bearish Technicals
Confidence
90%
Value
10/100

P/B of -0.05 indicates the company's liabilities exceed its assets.

Positives
  • Very low P/S ratio
Watchpoints
  • Negative Book Value
  • No Graham Number possible due to negative earnings
Future
15/100

Revenue growth of 3.8% is insufficient to offset massive operating losses.

Positives
  • Slight revenue growth
Watchpoints
  • Negative Forward P/E
  • Consistent EPS misses
  • Declining earnings progression
Past
5/100

Historical price action is a textbook example of a collapsing equity.

Positives
No standout positives identified.
Watchpoints
  • 99.5% loss over 5 years
  • 74.5% loss over 1 year
Health
10/100

Current ratio below 0.50 typically signals an immediate risk of insolvency.

Positives
  • Piotroski F-Score 4/9
Watchpoints
  • Current Ratio 0.24
  • Quick Ratio 0.22
  • Negative ROA
Dividend
0/100

Dividend strength is 0/100.

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • No capacity for dividends

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$2.5
Analyst Target
$3.5
Upside/Downside
+40.0%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for PIII and closest competitors.

Updated 2026-04-16
PII
P3 Health Partners Inc.
Primary
5Y
-99.5%
3Y
-95.6%
1Y
-74.5%
6M
-72.2%
1M
-4.2%
1W
-5.3%
MCT
Charming Medical Limited
Peer
5Y
+319.4%
3Y
+319.4%
1Y
+319.4%
6M
+319.4%
1M
0.0%
1W
0.0%
OFI
Orthofix Medical Inc.
Peer
5Y
-70.9%
3Y
-30.2%
1Y
-4.0%
6M
-14.4%
1M
+8.4%
1W
+5.5%
NPC
NeuroPace, Inc.
Peer
5Y
-38.5%
3Y
+219.8%
1Y
+43.9%
6M
+41.9%
1M
+8.2%
1W
+5.8%
IVV
Invivyd, Inc.
Peer
5Y
-91.6%
3Y
+46.1%
1Y
+248.5%
6M
0.0%
1M
-7.4%
1W
+37.5%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-11.9
PEG Ratio
N/A
P/B Ratio
-0.05
P/S Ratio
0.35
EV/Revenue
0.2
EV/EBITDA
-1.53
Market Cap
$507.93M

Profitability

Profit margins and return metrics

Profit Margin -10.14%
Operating Margin -39.98%
Gross Margin -4.12%
ROE -6952.57%
ROA -23.46%

Growth

Revenue and earnings growth rates

Revenue Growth +3.8%
Earnings Growth N/A
Q/Q Revenue Growth +3.81%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
N/A
Current Ratio
0.24
Weak
Quick Ratio
0.22
Poor
Cash/Share
$7.59

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.4B
Op. Margin
-40.0%
Net Margin
-19.6%
Total Assets
$0.7B
Liabilities
$0.8B
Equity
$-0.2B
Debt/Equity
-5.13x
Operating CF
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-14
$N/A
2026-03-26
$-23.02
-143.2% surprise
2025-11-13
$-9.67
-60.2% surprise
2025-08-14
$-6.23
-44.9% surprise

Healthcare Sector Comparison

Comparing PIII against 393 companies in the Healthcare sector (24 bullish, 129 neutral, 240 bearish)
Return on Equity (ROE)
-6952.57%
This Stock
vs
-101.52%
Sector Avg
+6748.8% (Excellent)
Profit Margin
-10.14%
This Stock
vs
-12.47%
Sector Avg
-18.7% (Weaker)
Revenue Growth
3.8%
This Stock
vs
124.21%
Sector Avg
-96.9% (Slower)
Current Ratio
0.24
This Stock
vs
4.56
Sector Avg
-94.6% (Weaker)

Similar Companies

Peer comparison within the same industry

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
NONE
2 analysts
TD Cowen
2026-04-02
Maintains
Hold Hold
Lake Street
2026-03-27
Maintains
Buy Buy
Lake Street
2025-11-17
Maintains
Buy Buy

Past News Coverage

Recent headlines mentioning PIII from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile